Sector News

Lubrizol Acquires Particle Sciences

September 9, 2015
Energy & Chemical Value Chain

The Lubrizol Corporation announces that it has acquired Particle Sciences, a leading contract drug development and manufacturing organization with a comprehensive suite of services for the formulation, analysis and production of complex drug delivery solutions. Headquartered in Bethlehem, PA, Particle Sciences is a global leader in complex formulations including drug eluting device product development as well as sterile and particulate drug products. This acquisition further expands Lubrizol LifeSciences’ pharmaceutical development capabilities, providing full service drug delivery solutions to the market across a variety of dosage forms.

“With the addition of Particle Sciences and the recent acquisition of Vesta, we are now able to offer customers a complete solution that is one of the most comprehensive in the industry,” stated Deb Langer, vice president and general manager, Lubrizol LifeSciences. “Additionally, the Particle Sciences acquisition allows us to leverage our core polymer chemistry into tailored solutions for novel implantable and dermal drug delivery systems for improved patient outcomes.”

Lubrizol LifeSciences has significantly expanded its capabilities through new products, state-of-the-art facilities, acquisitions and alliances. The combination of Lubrizol’s polymer expertise, Vesta’s quality medical manufacturing and Particle Sciences’ leadership in drug formulation development, allows LifeSciences to provide end-to-end solutions for success in the drug delivery market. With this unique combination, Lubrizol LifeSciences delivers comprehensive medical and pharmaceutical solutions, including to the growing combination product market.

“Particle Sciences and Lubrizol LifeSciences have worked together for several years providing various elements of an end-to-end solution from polymer supply through formulation and commercial manufacturing,” said Mark Mitchnick, chief executive officer, Particle Sciences. “With this transaction, Lubrizol LifeSciences acquires Particle Sciences’ extensive formulation, analytic and production assets for drug eluting devices, particulate, sterile and other complex drug products established over the last 10 years. We expect that coordinating all of this under one company will greatly benefit our customers.”

Particle Sciences will now be part of Lubrizol Advanced Materials but will retain its company name. Financial terms of the transaction were not disclosed.

Source: The Lubrizol Corporation

comments closed

Related News

July 14, 2024

Europe ethylene spot prices turn firmer on demand, feedstock, looming cracker turnarounds

Energy & Chemical Value Chain

European ethylene spot prices have firmed week on week on the back of better-than-expected demand amid higher feedstock values and an increasing focus on upcoming planned cracker maintenance outages. Spot deals this week have been reported at discounts of 32-35% on the pipeline, prior deals had been at discounts of around 38-39%.

July 14, 2024

Marcel Imwinkelried appointed new Siegfried CEO

Energy & Chemical Value Chain

He will succeed Reto Suter, who has led the Siegfried Group as CEO ad interim since the departure of Wolfgang Wienand on May 1, 2024. Suter will now focus on his role as Chief Financial Officer for Siegfried. Wienand will become CEO of Swiss competitor Lonza.

July 14, 2024

Honeywell acquires Air Products’ LNG technology, business for $1.8B

Energy & Chemical Value Chain

Honeywell Inc. (Charlotte, North Carolina) has reached agreement to acquire Air Products’ (Leigh Valley, Pennsylvania) liquefied natural gas process technology and equipment business for $1.81 billion. The deal is expected to close before the end of the year. The price represents a multiple of 13 times the unit’s estimated 2024 EBITDA.

How can we help you?

We're easy to reach